



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **TNO EXTENDS LICENSING AGREEMENT WITH GENEGO AGAIN AND PROVIDES TOXICOGENOMICS AND NUTRITIONAL SYSTEMS BIOLOGY SERVICES TO THEIR CLIENTS**

**St. Joseph, MI. December 4th, 2007** –GeneGo, Inc., the leading systems biology tools company, announced today that TNO, The European Nutrigenomics Organisation (NUGO) Consortium and The Netherlands Nutrigenomics Consortium (NGC) have extended their agreement with Genego. Further, the recently established Netherlands Toxicogenomics Centre (NTC) will soon acquire MetaCore and MetaDrug for applications in toxicogenomics.

This provides over 20 universities in Europe with access to MetaCore. GeneGo has a unique Rodent version of MetaCore with rat and mouse genes, protein complexes and interactions. This is the first species specific database which is not derived from ortholog matching. This level of detail is crucial for nutritionists and toxicologists who deduce human efficacy and toxicity based on animal models data.

‘TNO is routinely applying omics technologies to better understand the activities of nutrients and toxicants. A strong focus is on statistically and biologically driven bioinformatics towards drawing of relevant biological conclusions. We are coordinating the bioinformatics for the consortia mentioned above. MetaCore is a valuable add on to this portfolio and allows us to better understand omics data in the context of mechanisms of action. Within NuGO and NGC, Metacore is used by researchers in the fields of nutritional systems biology. Within NTC, it is used in the context of a variety of toxicological problems. Through interaction with these scientists, TNO is capable of further strengthen its scientific systems biology backbone in these areas.’ said Dr Rob Stierum’ Head Toxicogenomics

“We have established a close relationship with TNO over the years”, said Julie Bryant, GeneGo’s VP of Business development. “The projects we collaborate on include a study on cholesterol diet and drug effects on atherosclerosis and nutrigenomics. TNO is also using GeneGo products as part of their tox service offerings. We look forward to further collaborations and more publications.”

## **About GeneGo**

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore. For more information, please visit the company's web site at [www.genego.com](http://www.genego.com)

**MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™, MetaMiner™ and 1-2-3 Workflow™ are trademarks of GeneGo, Inc.**